Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management
about
Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart AssociationHeart disease and stroke statistics--2014 update: a report from the American Heart AssociationHeart disease and stroke statistics--2012 update: a report from the American Heart AssociationA 26-year-old woman with recurrent loss of consciousness.Trigger-specific risk factors and response to therapy in long QT syndrome type 2.β-blockers protect against dispersion of repolarization during exercise in congenital long-QT syndrome type 1.Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndromeLong QT syndrome: a Korean single center study.Long QT syndrome: how effective therapy in a single patient favorably influenced the long-term clinical course and genetic understanding of this hereditary disorder.Inpatient detection of cardiac-inherited disease: the impact of improving family history takingImproved Clinical Risk Stratification in Patients with Long QT Syndrome? Novel Insights from Multi-Channel ECGsNot all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprololNext generation diagnostics in inherited arrhythmia syndromes : a comparison of two approaches.Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome.Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies.Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statisticsMolecular Pathophysiology of Congenital Long QT Syndrome.Stability of propranolol in extemporaneously compounded suspensions.Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis.Spontaneous initiation of premature ventricular complexes and arrhythmias in type 2 long QT syndrome.Ten-year experience in atenolol use and exercise evaluation in children with genetically proven long QT syndrome.The role of sympathectomy in long QT syndrome.Clinical and molecular genetic risk determinants in adult long QT syndrome type 1 and 2 patients : Koponen et al. Follow-up of adult LQTS patients.
P2860
Q22306356-4B43E005-0A61-4EBB-AC01-639F86BE5823Q29547691-24A24C09-CB66-4E59-BAA9-DA5C1120BE93Q29547909-F779A7AE-1A38-4474-ACAE-2C475C34D4D8Q30460335-9FFD878A-53C8-4809-8E68-2DF76D7C1CFAQ33159219-1BDD2264-FC02-4729-9446-37C5E5F965B2Q33160110-AA57DE79-31B2-4691-AF47-7FB05EB0C317Q33161560-7BF13015-D300-4E95-A450-A0929D701567Q33163411-9A3125F6-A4C8-440E-B167-5414A13B713FQ33166092-83606469-59ED-47A2-AD96-A1D540AC0EDEQ33166859-1FB546EE-51A0-4F52-8245-A3BFE2188B92Q33167382-B0B22D23-A5AA-4B4E-BEDD-C298C761CBEEQ34307224-7B3A6675-4119-4D72-B84C-3E6768C7CB35Q36537110-90DF2FE5-A687-448F-BEB3-2F510311E32DQ36949265-6C9FB6A2-F5D0-476E-B4B5-63CA3D58424CQ36975788-6511DC92-612E-41AC-B3D5-FAE0476F94C8Q37380061-16BE2AC4-F8B4-4611-B056-0884573B3F9DQ38997049-96B5F794-D8B5-42B5-B0B6-50637A943F35Q40017242-99C00236-16A4-4BDC-9E09-34D7689B55CDQ43179403-8F63189C-2D9F-4646-9D93-268F9EF3DF35Q46086763-7B097003-4D50-434A-850C-07FE6F1320A2Q47117871-E6D212BC-66B6-40C8-BFF8-DB9BB28CEA79Q47143699-3E29FBF6-DDC2-4538-99C0-657DF7DCF3D2Q55053440-7C6A6D8C-4D80-4499-AA46-F3A25A4E03F7
P2860
Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Beta-blocker efficacy in high- ...... cations for patient management
@ast
Beta-blocker efficacy in high- ...... cations for patient management
@en
type
label
Beta-blocker efficacy in high- ...... cations for patient management
@ast
Beta-blocker efficacy in high- ...... cations for patient management
@en
prefLabel
Beta-blocker efficacy in high- ...... cations for patient management
@ast
Beta-blocker efficacy in high- ...... cations for patient management
@en
P2093
P2860
P1476
Beta-blocker efficacy in high- ...... cations for patient management
@en
P2093
Arthur Moss
Ilan Goldenberg
International LQTS Registry Investigators
James Bradley
Jennifer L Robinson
Mark Andrews
Slava Polonsky
P2860
P304
P356
10.1111/J.1540-8167.2010.01737.X
P577
2010-03-05T00:00:00Z